Hyperion Therapeutics, Inc. reported completion of data analysis for its Phase 2 clinical trial designed to evaluate the safety, tolerability and ammonia scavenging effects of HPN-100 versus BUPHENYL(R) (sodium phenylbutyrate),...
SCOTTSDALE, Ariz., Nov. 11, 2008 (GLOBE NEWSWIRE) -- Medicis (NYSE:MRX) today announced that the Company is scheduled to present at the 2008 Credit Suisse Healthcare Conference in Phoenix, Arizona. A live webcast of its...
| Request a Trial to NEW EDGAR Online Pro Form 8-K for MEDICIS PHARMACEUTICAL CORP Results of Operations and Financial Condition Item 2.02 Results of Operations and Financial Condition. On November 10, 2008, Medicis...
Medicis Pharmaceutical Corporation, together with its subsidiaries, operates as a specialty pharmaceutical company in the United States and Canada. It develops and markets products for the treatment of dermatological,...
financial results conference call. Factors may cause actual results to differ materially from those projected in forward-looking statements. The strong prescription growth of SOLODYN is not really reflected in the total revenue...
November 11, 2008 | about stocks: Q3 2008 Earnings Call Transcript Executives Jonah Shacknai – Chairman and CEO Mark Prygocki – EVP and COO Rick Peterson – EVP, CFO and Treasurer Analysts Corey Davis – Natixis Michael Tong –...
Medicis Earnings Conference Call (Q3 2008) Scheduled to start Mon, Nov 10, 2008, 5:15 pm Eastern After the event has finished, the audio will be available from this page until Wed, Nov 11, 2009 Medicis Pharmaceutical...
Friday October 31, 5:51 pm ET NEW YORK, Oct. 31, 2008 (GLOBE NEWSWIRE) -- News) and certain officers of the Company have been sued in a class action on behalf of purchasers of Medicis common stock of the Company for the period...
Friday October 31, 5:51 pm ET NEW YORK, Oct. 31, 2008 (GLOBE NEWSWIRE) -- News) and certain officers of the Company have been sued in a class action on behalf of purchasers of Medicis common stock of the Company for the period...